A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma

European Journal of Haematology

Volumn 66, Issue 1, 2001, Pages 24-30

  Niitsu, Nozomi ^a,b   Iijima, Kimiko ^a   Chizuka, Aki ^a  

^a TOHO UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Aggressive non Hodgkin's lymphoma; International Prognostic Index; Prognostic factor; Soluble interleukin 2 receptor

Indexed keywords

INTERLEUKIN 2 RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LIFE TABLES; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; LYMPHOMA, HIGH-GRADE; LYMPHOMA, INTERMEDIATE-GRADE; LYMPHOMA, LOW-GRADE; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROCARBAZINE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, HIGH-ENERGY; RECEPTORS, INTERLEUKIN-2; REMISSION INDUCTION; SOLUBILITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0035141983     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.00334.x     Document Type: Article

References (30)

1. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells
2. T cell growth factor receptors. Quantitation, specificity, and biological relevance
3. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro
4. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma
5. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia
6. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma
7. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia
8. Serum soluble interleukin-2 receptor levels in patients with adult T-cell leukemia and human T-cell leukemia/lymphoma virus type-I seropositive healthy carriers
9. Impaired expression of high affinity interleukin 2 receptor on activated lymphocytes from patients with systemic lupus erythematosus
10. The soluble interleukin-2 receptor: Biology, function, and clinical application
11. A predictive model for aggressive non-Hodgkin's lymphomas. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
12. A revised European American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
13. Report of the committee on Hodgkin's disease staging classification
14. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma
15. COP-BLAM regimen combined with granulocyte colony-stimulating factor (G-CSF) and highgrade non-Hodgkin's lymphoma
16. Individual comparisons by ranking methods
17. Evaluation of survival data and two new rank order statistics arising in its consideration
18. Regression models and life tables
19. Mutationd of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
20. Expression of bcl-2 protein and Fas antigen in non-Hodgkin's lymphoma
21. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma
22. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma
23. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
24. Soluble interleukin 2 receptors in patients with malignant lymphoma
25. Serum-soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies
26. Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin's lymphoma
27. Clinical studies of adult T-cell leukemia-lymphoma. (2) Hypercalcemia associated with adult T-cell leukemia
28. Serum levels of soluble interleukin-2 receptor in Hodgkin's disease. Relationship with clinical stage, tumor burden, and treatment outcome
29. Soluble interleukin 2 receptors in patients after bone marrow transplantation
30. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro